Disentangling the stringent response to engineer novel anti-persister drugs

Project description

Novel mechanistic insight into antibiotic resistance

Antibiotic-resistant bacteria are a growing health concern worldwide with many healthcare implications. Emerging evidence indicates that dormant bacteria subpopulations which are difficult to eradicate with conventional means are the primary source of antibiotic resistance. The EU-funded DiStRes project is investigating the RelA/SpoT (RSH) proteins that promote the stringent response in bacteria and modulate cell metabolism through the (p)ppGpp. Through a combined microbiology and structural biology approach, researchers will focus on the molecular mechanisms of ppGpp synthesis and hydrolysis. DiStRes will not only shed light on the mechanism of drug resistance, but also help design and screen novel drug candidates that target the stringent response in persistent bacteria.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• engineering and technology › civil engineering › structural engineering
• natural sciences › biological sciences › microbiology › bacteriology
• natural sciences › biological sciences › biochemistry › biomolecules › proteins › enzymes

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2019-COG - ERC Consolidator Grant

Call for proposal

ERC-2019-COG
See other projects for this call

Funding Scheme

ERC-COG - Consolidator Grant

Host institution

UNIVERSITE LIBRE DE BRUXELLES

Address

Avenue Franklin Roosevelt 50
1050 Bruxelles
Belgium

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 2 000 000

Beneficiaries (1)

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU contribution

€ 2 000 000

Address

Avenue Franklin Roosevelt 50
1050 Bruxelles

Activity type

Higher or Secondary Education Establishments